MoonLake Immunotherapeutics (MLTX) Revenue History
Annual and quarterly revenue from 2020 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MLTX Revenue Growth
Revenue Breakdown (FY 2025)
MLTX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
MLTX Revenue Analysis (2020–2025)
As of May 8, 2026, MoonLake Immunotherapeutics (MLTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, MLTX's historical revenue data shows various trends over time.
Revenue diversification analysis shows MLTX's business is primarily driven by License (100%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including UCB, NKTR (-43.9% YoY), and ARQT (+95.3% YoY). Compare MLTX vs UCB →
MLTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MLTXCurrent | $0 | - | - | - | |
 UCB | $1.5B | - | - | 27.5% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 DAWN | $158M | +20.6% | - | -80.8% |
MLTX Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-2,616,000 | - | $-244,834,000 | - |
| 2024 | $0 | - | $0 | - | $-143,091,082 | - |
| 2023 | $0 | - | $0 | - | $-54,123,096 | - |
| 2022 | $0 | - | $0 | - | $-65,061,417 | - |
| 2021 | $0 | - | $-4,971 | - | $-53,577,012 | - |
| 2020 | $0 | - | $0 | - | $-105,755 | - |
See MLTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MLTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MLTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMLTX — Frequently Asked Questions
Quick answers to the most common questions about buying MLTX stock.
Is MLTX's revenue growth accelerating or slowing?
MLTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is MLTX's long-term revenue growth rate?
MoonLake Immunotherapeutics's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is MLTX's revenue distributed by segment?
MLTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2025 are available for download. Segment mix reveals concentration and diversification trends.